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Humankind has gone through major airborne virus pandemics in the modern era. Coronavirus
outbreaks have been registered in 2003 [severe acute respiratory syndrome (SARS)], 2009 [Middle
East respiratory syndrome (MERS)], and 2019/2020 ongoing [CoV disease (COVID-19)]. Influenza
outbreaks were documented in 1918 (post-World War I Spanish flu, H1N1 virus), 1957–1958
(Asian flu, H2N2 virus), 1968 (the Hong Kong flu, H3N2 virus), and 2009 (the swine flu, H1N1
virus). These viruses can only affect humans after mutating in their usual animal hosts, presenting
as a zoonotic disease in the beginning. Unknown to the human immune system, they spread swiftly,
resulting in outbreaks. Fatality rates vary from >30% for MERS, ∼10% for the 1918 Spanish flu,
10% for SARS to <1% for the 2009 MERS. The number of infected people was 700 or 500 million
with 2009’s or 1918’s H1N1 virus, respectively, 8,000 with SARS-CoV-1, and 2,500 withMERS-CoV.
As of June 29th, according to the World Health Organization’s daily situation report no. 161,
SARS-CoV-2 has infected 10 million people, with a 4.98% case fatality rate (https://www.who.int/
emergencies/diseases/novel-coronavirus-2019/situation-reports).
Coronavirus (CoV) and influenza virus (IV) are neurotropic (1, 2). Experimental studies using
transgenic mice showed that SARS- and MERS-CoV intranasal administration was followed by the
invasion of the olfactory neuroepithelium and, ultimately, of the brain (2). Coronavirus could also
access the central nervous system by transsynaptic transfer, starting at peripheral nerve endings
(2). At later stages, invasion via the bloodstream likely involves angiotensin-converting enzyme
2 (ACE2) receptors (1). A schematic representation can be found in Figure 1. Noteworthy, the
brainstem shows the highest level of viral particles. Impairment of the cardiorespiratory nuclei, the
nucleus ambiguous and the nucleus of the solitary tract, in particular, may contribute to respiratory
distress (2).
It does not surprise that patients develop a variety of neurological symptoms (1). Indeed,
SARS-CoV-2 is likely to infect the central nervous system early in the disease’s course
(2). Results from a large survey involving 2,343 European neurologists revealed headache
(61.9%), myalgia (50.4%), anosmia (49.2%), ageusia (39.8%), impaired consciousness (29.3%),
and psychomotor agitation (26.7%) as the most frequent neurological findings (3). In a
recent experiment, viral replication within neurons soon after infection by SARS-CoV-2 in
a human-induced pluripotent stem cell (iPSC)-derived BrainSphere model (4), supporting
virus neurotropism. The neural consequences of viral infection were further tested in 47
patients with mild (n = 20), moderate (n = 9), or severe (n = 18) COVID-19, which
were compared to 33 controls (5). Plasma levels of neurofilament light chain protein,
a marker of neuronal injury, and glial fibrillary acidic protein, a marker of astrocyte
damage, were higher in moderately or severely affected patients. Interestingly, astrocyte
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FIGURE 1 | Schematic representation of the most likely routes to neural invasion by SARS-CoV-2. Left: orange depicts the olfactory neuroepithelium route; blue
depicts the bloodstream route after lung invasion (reproduced from https://sq.wikipedia.org/wiki/Lemza). Right: red circles indicate brain areas with the highest
SARS-CoV titers (figure kindly provided by the Servier Medical Art Department). All figures are reproduced under a CC BY-SA license.
damage appeared to precede neuronal death. These findings
suggest that brain injury may be more common than previously
thought. COVID-19 should be viewed as a multisystemic disease,
the involvement of the nervous system being noteworthy.
Acute disseminated encephalomyelitis has been observed after
SARS-CoV-2 infection in a patient without prominent clinical
pulmonary symptoms (6). Some patients with COVID-19 have
developed Guillain–Barré syndrome (7). These findings suggest
that neuronal damage may concern not only the olfactory system
and brainstem nuclei, as was initially suggested (8).
Olfactory loss may be the earliest neurological sign in
COVID-19. One study conducted during the early pandemic
in Italy showed that 13.5% of a small sample of patients
with COVID-19 had developed hyposmia (9). A later study
found olfactory dysfunction in 85.6% of 417 mild-to-moderate
COVID-19 patients recruited from 12 European hospitals (10).
A recent systematic review of 10 studies including 1,627 patients
reported a 52.73% (95% CI, 29.64–75.23%) hyposmia prevalence
in COVID-19 patients (11). Interestingly, hyposmia may precede
other COVID-19 symptoms in a large number of cases (10),
highlighting the earliness in brain tissue invasion and the
relevance of its awareness.
The long-term consequences of coronavirus infections may
be serious, as suggested by the observation that certain CoV
strains are linked to neurodegenerative changes resulting in
multiple sclerosis (1). The first observations date back to the
1980s. More recent studies have identified CoV-OC43, which
shows serological cross-reactivity with SARS-CoV (12), more
often in brain tissue of multiple sclerosis patients than that in
control subjects (1). Both direct and indirect pathophysiological
mechanisms have been proposed (13). Cross-reactivity between
viral antigens and myelin may be a key mechanism (13).
Febrile or afebrile seizures, myelitis, meningitis, encephalitis,
Guillain–Barré syndrome, and depression are among the
manifestations observed upon IV infection. It is noteworthy
that brain disease can develop even in the absence of
respiratory symptoms (1). Seasonal IV infection can also lead
to neurological complications. One study reported neurological
alterations in 21 patients of a wide range of age, observing
encephalitis as the most frequent clinical sign (1). Fifty percent
of them showed neurological sequelae, sometimes including
parkinsonism. Neuroinflammation after the activation of the
microglia and other immune cells promotes neuronal death
and protein aggregation (1), which may favor neurodegenerative
diseases development in due course, as below discussed further.
Parkinson’s disease (PD) affects nearly 6.1 million people
globally. Our understanding of the pathophysiology of the
disease has radically changed in recent decades. We now
believe that PD is an umbrella disorder encompassing many
genetic–molecular entities affecting many systems, resulting in
a broad spectrum of motor and nonmotor features (14). The
main histological finding is the presence of intracellular Lewy
bodies composed of misfolded α-synuclein protein aggregates
(14). Neuroinflammation, apoptosis, mitochondrial dysfunction,
altered calcium homeostasis, inadequate protein degradation,
and synaptic pathobiology have been cited as mechanisms
resulting in either cell death and α-synuclein deposition or
both (14).
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Infections may play a role in PD development. A recent meta-
analysis has shown that individuals with ongoing infections had
a 20% higher PD risk compared with controls (15). Interestingly,
IV infection was identified as one event that increased the risk of
PD (15).
According to a recent theory, PD onset may be triggered by
exposure to air pollutants, pesticides, heavy metals, head trauma,
gastrointestinal microbiota perturbations, and pathogens (16)
like the airborne viruses already discussed. The correlation
between the routes of viral brain invasion and the findings of
Braak and colleagues further supports this hypothesis. According
to these authors, Lewy bodies can be first found at the
brainstem and the olfactory cortex, long before damage to the
substantia nigra results in the typical motor symptoms (17).
As discussed earlier, viruses may reach the brainstem via a
transsynaptic route and the olfactory cortex via the olfactory
neuroepithelium (1, 2). While PD development requires not only
triggers but also facilitators and aggravators (16), these pieces of
evidence reinforce the potential connection with an airborne viral
infection. So far, a potential triggering effect of CoV infection has
not been reported. Notwithstanding, the above-discussed data
support this idea.
What way viral infection may lead to developing a
neurodegenerative disease is unclear. A local immune response
leading to neuroinflammation is a likely candidate (13). Recent
data show that α-synuclein may participate in the immune
response, and infections may induce its upregulation (16). In
turn, this molecule may activate microglia (18). Inflammatory
cytokines and chemokines produced by microglia cells would
amplify the inflammatory response (19), leading to neuronal
death (20). In addition, neuroimmune responses to infection
may lead to glutamate excitotoxicity (13), linked to neuronal
degeneration (14).
The extent to which the novel SARS-CoV-2 respiratory virus
pandemic is implicated in PD development should not be
overlooked. This novel virus may infect millions of people,
many likely being ever unaware. As said, central nervous system
infection may occur in the absence of other symptoms (2).
Noteworthy, smell alteration is being retrospectively recalled as
an early symptom prodromal to later respiratory distress by
infected people developing COVID-19 (9). In these cases, even
if the immune system can control the infection and prevent an
overt disease, the triggering of PD may have already taken place.
Here again, smell alteration is early recalled by PD patients, as
manifesting even years before PD diagnosis (14). The triggering
effects may escalate upon repetitive exposure to the virus over the
lifespan. Even if such effects are mild or moderate, the number
of people exposed, reaching several million, suggests that the
implications on PD should not be overlooked.
In sum, infection with CoV or IV respiratory viruses
may increase the risk of developing PD over a lifetime.
Pandemics of respiratory viruses appear a hallmark of the
modern era and may be expected to reappear over time,
according to experts. Besides the death toll, these pandemics
may contribute to an increased worldwide burden of PD,
which may only become noticeable many decades after
the outbreaks. Health systems should be ready to tackle
an eventual increase in PD burden. Notwithstanding,
the infected population at risk for developing PD is
an interesting target for testing disease-modifying or
neuroprotective treatments.
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